Cited by CrossRef (6)
- Yanying Liu, Binyang Qing, Weiwei Ke, Mian Wang. MEK inhibitor trametinib combined with PI3K/mTOR inhibitor BEZ-235 as an effective strategy against NSCLC through impairment of glucose metabolism. Cellular Signalling 2024;124:111415

- Xin Wen, Si Chen, Xueting Chen, Hui Qiu, Wei Wang, Nie Zhang, Wanming Liu, Tingting Wang, Xin Ding, Longzhen Zhang. ITGB5 promotes innate radiation resistance in pancreatic adenocarcinoma by promoting DNA damage repair and the MEK/ERK signaling pathway. Front. Oncol. 2022;12

- Joshua Zhang, Lily Darman, Md Hassan, Urs Von Holzen, Niranjan Awasthi. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review). Oncol Rep 2023;50

- Bin Sun, Hongrui Chen, Wei Gao, Yunqi Li, Chen Hua, Xiaoxi Lin. An immortalized adipose-derived stem cells line from the PIK3CA-related overgrowth spectrum: Unveiling novel therapeutic targets. Biochemistry and Biophysics Reports 2024;40:101869

- Kexun Zhou, Yingping Liu, Shiman Yuan, Ziyu Zhou, Pengfei Ji, Qianhan Huang, Feng Wen, Qiu Li. Signalling in pancreatic cancer: from pathways to therapy. Journal of Drug Targeting 2023;31:1013

- Al Jarroudi Ouissam, Chibani Hind, Brahmi Sami Aziz, Afqir Said. Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?. Ther Adv Med Oncol 2024;16
